Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Inclusion Criteria: * Informed Consent Form signed by the participant or participant's legal representative; if the participant was under the age of 18 but capable of providing assent, signed assent from the participant. * Participant (or caretaker) must have been willing to comply with all protocol requirements. * Participants who completed the SD-005 study (on study drug at Visit 5, approximately 90 days from baseline). Exclusion Criteria: * Participants who did not meet the entry criteria outlined above. * Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at the final visit for Study SD-005 for female participants of childbearing potential and repeated at screening/baseline visit of Study SD-006 if these visits did not occur on the same day). * Female participants of childbearing potential who were not abstinent or not practicing a medically acceptable method of contraception.